FGF23 and neoplasm: Here, we describe the case of a 69-year-old woman who presented with persistent hypophosphatemia, renal phosphate wasting, and elevated intact FGF-23 levels despite a normal C-terminal assay, ultimately managed successfully with burosumab in the absence of tumor localization.